Despite a decrease in monocytes and M2-like TAMs, Axatilimab, which targets the CSF1R-CSF1 axis to block monocyte recruitment to the tumor, also showed no added response in combination with immunotherapy (NCT03238027) (62). Here, CSF1 is linked to neoplasm.